Home Cart Sign in  
Chemical Structure| 1421919-75-6 Chemical Structure| 1421919-75-6

Structure of KPT-276
CAS No.: 1421919-75-6

Chemical Structure| 1421919-75-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KPT-276, analog of KPT-185, is a CRM1 blocker and acts as an orally bioavailable selective inhibitor of nuclear export (SINE) by irreversibly binding to CRM1.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KPT-276

CAS No. :1421919-75-6
Formula : C16H10F8N4O
M.W : 426.26
SMILES Code : O=C(N1CC(F)(F)C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
MDL No. :MFCD27937049

Safety of KPT-276

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
KT-276 is a derivative of PKT-185, designed as an orally available and selective inhibitor targeting the nuclear export (SINE) function. Specifically, it acts as a CRM1 antagonist, irreversibly binding to and inhibiting the CRM1 protein, which plays a crucial role in the nuclear export of numerous proteins and RNA[1].
Target
  • CRM1

In Vitro:

Cell Line
Concentration Treated Time Description References
Human myeloma cell lines (HMCLs) 15.625 nM to 1000 nM 72 hours KPT-276 significantly reduced the viability of 12 HMCLs, with a median IC50 value of approximately 160 nM. PMC3922416
SKBR3 10 μM 24 hours To evaluate the effect of KPT-276 on SKBR3 cell apoptosis, results showed that KPT-276 significantly induced apoptosis PMC3954411
SKBR3 0.01-100 μM 72 hours To evaluate the effect of KPT-276 on SKBR3 cell growth, results showed that KPT-276 significantly inhibited cell growth PMC3954411
MDA-MB-231 0.01-100 μM 72 hours To evaluate the effect of KPT-276 on MDA-MB-231 cell growth, results showed that KPT-276 significantly inhibited cell growth PMC3954411
MCF7 0.01-100 μM 72 hours To evaluate the effect of KPT-276 on MCF7 cell growth, results showed that KPT-276 significantly inhibited cell growth PMC3954411
WSU-FSCCL 0–150 nM 72 hours Evaluate the cytotoxicity and apoptosis effects of KPT-276 in combination with DEX or EVER, showing significantly enhanced apoptosis PMC5584550
WSU-DLCL2 0–150 nM 72 hours Evaluate the cytotoxicity and apoptosis effects of KPT-276 in combination with DEX or EVER, showing significantly enhanced apoptosis PMC5584550
MesoII cells 0.36 ± 0.04 μmol/L (IC50) 72 hours To evaluate the inhibitory effect of KPT-276 on DMPM cell growth, results showed that KPT-276 significantly inhibited the growth of MesoII cells with an IC50 value of 0.36 ± 0.04 μmol/L PMC4537003
STO cells 0.24 ± 0.02 μmol/L (IC50) 72 hours To evaluate the inhibitory effect of KPT-276 on DMPM cell growth, results showed that KPT-276 significantly inhibited the growth of STO cells with an IC50 value of 0.24 ± 0.02 μmol/L PMC4537003
Motor neurons 50 nM 3 days Rescued PFN1C71G-dependent axonal outgrowth defects PMC6707192
Motor neurons 50 nM 6 hours Inhibition of nuclear export fully rescued TDP-43 cytoplasmic mislocalization PMC6707192
DIPG 6 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
DIPG 4 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
BT 245 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
AGBM1 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
BT 172 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
BT 159 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
BT 145 0.1 nM–100 μM 5 days Evaluate the in vitro efficacy of SINE compounds on GBM cells, showing dose-responsive growth inhibition in all 7 GBM lines PMC4482855
Neurons 0.1 to 1000 nM 24 hours To evaluate the toxicity of KPT-276 in neurons, results showed no toxicity at concentrations ranging from 0.1 to 1000 nM. PMC4522902

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nonobese diabetic severe combined immunodeficient–interleukin 2 receptor gamma null mice (NOD-SCID gamma [NSG] mice) BT 145 intracranial xenograft model Oral gavage initial dose 50 mg/kg, escalated to 75 mg/kg after one week 3 times per week (Monday, Wednesday, Friday), continued treatment Evaluate the in vivo efficacy of KPT-276 in a GBM xenograft model, showing significant tumor growth suppression and prolonged animal survival PMC4482855
Mice Experimental autoimmune encephalomyelitis (EAE) Oral gavage 75 mg/kg Every other day for 12 days To evaluate the therapeutic effect of KPT-276 in the EAE model, results showed significant attenuation of disease progression and preservation of axonal integrity. PMC4522902
ICR-SCID mice WSU-DLCL2 subcutaneous tumor model and WSU-FSCCL systemic model Oral 75 and 150 mg/kg Once daily for ten consecutive days with a one day break prior to start of a new cycle Evaluate the anti-tumor activity of KPT-276 in NHL xenograft models, showing comparable or superior anti-tumor potential to CHOP regimen PMC5584550
NOD/SCID mice A375 or CHL-1 human melanoma xenograft models Oral 75 mg/kg Three times weekly until tumor volume reached 1500 mm³ KPT-276 significantly inhibited the growth of A375 and CHL-1 human melanoma xenografts. PMC4109950
NOD-SCID mice H1975 cell xenograft model Oral 100 mg/kg 3 times a week for 3 weeks To examine the efficacy and side effects of KPT-276 in vivo. Results showed that KPT-276 significantly inhibited tumor growth with no significant mouse body weight loss or other side effects. PMC3942386
Nude mice Subcutaneous STO xenograft model Oral 50 mg/kg 5 days a week for 3 weeks To evaluate the anti-tumor activity of KPT-276 in subcutaneous STO xenograft model, results showed that KPT-276 significantly inhibited tumor growth with a tumor volume inhibition rate of 84% PMC4537003

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.23mL

11.73mL

2.35mL

1.17mL

23.46mL

4.69mL

2.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories